Voltaren
FollowVoltaren Archives
GSK, Novartis ordered to pay $4.5m for misleading Voltaren claims
Novartis and GSK penalised for making false and misleading claims in the marketing of Voltaren Osteo Gel.
GSK and Novartis face penalties for misleading consumers on Voltaren products
GSK and Novartis admit that they breached Australian Consumer Law in marketing of Voltaren.
